Pfizer is licensing an AI startup's drug discovery software to speed up antibody design
Colleen Cabi
·
2026-06-05
·
via Quartz
Pfizer will gain early access to Chai-3, a previously undisclosed model that doubles the antibody design succ…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。